CO5261544A1 - N-RENTED PEPTIDES THAT HAVE ANTIANGIOGEN ACTIVITY - Google Patents
N-RENTED PEPTIDES THAT HAVE ANTIANGIOGEN ACTIVITYInfo
- Publication number
- CO5261544A1 CO5261544A1 CO00088047A CO00088047A CO5261544A1 CO 5261544 A1 CO5261544 A1 CO 5261544A1 CO 00088047 A CO00088047 A CO 00088047A CO 00088047 A CO00088047 A CO 00088047A CO 5261544 A1 CO5261544 A1 CO 5261544A1
- Authority
- CO
- Colombia
- Prior art keywords
- group
- alanyl
- xaa1
- xaa2
- carbonyl
- Prior art date
Links
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
- -1 N-acetylamino Chemical group 0.000 abstract 8
- 125000001980 alanyl group Chemical group 0.000 abstract 3
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- 150000001413 amino acids Chemical class 0.000 abstract 3
- 125000002252 acyl group Chemical group 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 2
- 125000004801 4-cyanophenyl group Chemical group [H]C1=C([H])C(C#N)=C([H])C([H])=C1* 0.000 abstract 1
- 125000000030 D-alanine group Chemical group [H]N([H])[C@](C([H])([H])[H])(C(=O)[*])[H] 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000000539 amino acid group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000000392 cycloalkenyl group Chemical group 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 abstract 1
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 abstract 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 abstract 1
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 abstract 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000002072 seryl group Chemical group 0.000 abstract 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Reproductive Health (AREA)
- Zoology (AREA)
- Communicable Diseases (AREA)
- Toxicology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Ophthalmology & Optometry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Un compuesto que tiene la fórmula: Xaao-Xaa1-Xaa2-Xaa3-Xaa4-Xaa5-Xaa6-Xaa7-Xaa8-Xaa9-Xaa10 (I), 1 2 3 4 5 6 7 8 9 ó una sal farmacéuticamente aceptable de éste en donde por lo menos un enlace amida de un residuo aminoácido representado por Xaa3, Xaa4, Xaa5, Xaa6, Xaa7, Xaa8, Xaa9, Xaa10 se encuentra N-alquilado; Xaa1 está ausente ó Xaa1 se selecciona del grupo conformado por hidrógeno, N metilprolil, y un grupo acilo, en donde el grupo acilo se selecciona del grupo conformado por R1-(CH2)n-C(O)-, en donde n es un número entero entre 0 y 8 y R1 se selecciona del grupo conformado por N-acetilamino, alcoxi, alquil, aril, carboxi, cicloalquenil, cicloalquil, heterociclo, e hidroxi; y R2-CH2CH2-O-( CH2CH2-O)p-CH2-C(O)-, en donde p es un número entero entre 1 y 8 y R2 se selecciona del grupo conformado por hidrógeno, N-acetilamino, y alquil; con la condición de que Xaa1 está ausente solamente cuando Xaa2 es N-(R3)-prolil; Xaa2 es un aminoácido N-alquilado seleccionado del grupo conformado por N-(R3)- alanil, N-(R3)-glicil, N-(R3)-norvalil, y N-(R3)-prolil, en donde R3 es alquil C1-C5; ó Xaa2 un aminoácido no alquilado en N seleccionado del grupo conformado por ß -alanil, D-alanil, 4-aminobutiril, (1R, 3S)-1 -aminociclopentano-3-carbonil, (1S, 3R)-1 -aminociclopentano-3-carbonil, (1R, 4S)-1 -aminociclopent-2-eno-4-carbonil, (1S, 4R)-1 -aminociclopent-2-eno-4-carbonil, asparaginil, 3-(4-clorofenil)alanil, 3-(4-cianofenil)alanil, glutaminil, glutamil, glicil, 4-hidroxiprolil, 3-(4-metilfenil)alanil, prolil, seril, y treonil; Xaa3 es un aminoácido N-alquilado seleccionado del grupo conformado por N-(R3)-alanil, N-(R3)-glicil, N-(R3)-leucil, y N-(R3)-fenilalanil, en donde R3 corresponde a lo previamente definido; ...A compound having the formula: Xaao-Xaa1-Xaa2-Xaa3-Xaa4-Xaa5-Xaa6-Xaa7-Xaa8-Xaa9-Xaa10 (I), 1 2 3 4 5 6 7 8 9 or a pharmaceutically acceptable salt thereof where at least one amide bond of an amino acid residue represented by Xaa3, Xaa4, Xaa5, Xaa6, Xaa7, Xaa8, Xaa9, Xaa10 is N-alkylated; Xaa1 is absent or Xaa1 is selected from the group consisting of hydrogen, N methylprolil, and an acyl group, wherein the acyl group is selected from the group consisting of R1- (CH2) nC (O) -, where n is an integer between 0 and 8 and R1 is selected from the group consisting of N-acetylamino, alkoxy, alkyl, aryl, carboxy, cycloalkenyl, cycloalkyl, heterocycle, and hydroxy; and R2-CH2CH2-O- (CH2CH2-O) p-CH2-C (O) -, where p is an integer between 1 and 8 and R2 is selected from the group consisting of hydrogen, N-acetylamino, and alkyl; with the proviso that Xaa1 is absent only when Xaa2 is N- (R3) -prolil; Xaa2 is an N-alkylated amino acid selected from the group consisting of N- (R3) -alanyl, N- (R3) -glynyl, N- (R3) -norvalyl, and N- (R3) -prolil, where R3 is alkyl C1-C5; or Xaa2 an N-alkylated amino acid selected from the group consisting of β-alanyl, D-alanyl, 4-aminobutyryl, (1R, 3S) -1-aminocyclopentane-3-carbonyl, (1S, 3R) -1-aminocyclopentane-3 -carbonyl, (1R, 4S) -1-amino-cyclopent-2-ene-4-carbonyl, (1S, 4R) -1-amino-cyclopent-2-ene-4-carbonyl, asparaginyl, 3- (4-chlorophenyl) alanyl, 3- (4-cyanophenyl) alanyl, glutaminyl, glutamyl, glycyl, 4-hydroxypropyl, 3- (4-methylphenyl) alanyl, prolyl, seryl, and threonyl; Xaa3 is an N-alkylated amino acid selected from the group consisting of N- (R3) -alanyl, N- (R3) -glynyl, N- (R3) -leucyl, and N- (R3) -phenylalanyl, where R3 corresponds to the previously defined; ...
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US44709999A | 1999-11-22 | 1999-11-22 | |
| US70264900A | 2000-10-31 | 2000-10-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO5261544A1 true CO5261544A1 (en) | 2003-03-31 |
Family
ID=27034850
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO00088047A CO5261544A1 (en) | 1999-11-22 | 2000-11-20 | N-RENTED PEPTIDES THAT HAVE ANTIANGIOGEN ACTIVITY |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP1242455A1 (en) |
| JP (1) | JP2003514920A (en) |
| AR (1) | AR026901A1 (en) |
| AU (1) | AU1791301A (en) |
| BR (1) | BR0010934A (en) |
| CA (1) | CA2386893A1 (en) |
| CO (1) | CO5261544A1 (en) |
| HK (1) | HK1050902A1 (en) |
| MX (1) | MXPA02005139A (en) |
| WO (1) | WO2001038397A1 (en) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020183242A1 (en) * | 2001-04-11 | 2002-12-05 | Jack Henkin | Peptide antiangiogenic drugs |
| US20030119746A1 (en) * | 2001-10-31 | 2003-06-26 | Fortuna Haviv | Hepta-and octapeptides having antiangiogenic activity |
| US7169888B2 (en) | 2001-10-31 | 2007-01-30 | Abbott Laboratories | Tetra-, penta-, hexa- and heptapeptides having antiangiogenic activity |
| US7122625B2 (en) | 2001-10-31 | 2006-10-17 | Abbott Laboratories | Hexa-, hepta-, and octapeptides having antiangiogenic activity |
| US7001984B2 (en) | 2001-10-31 | 2006-02-21 | Abbott Laboratories | Di-, tri-, and tetra-peptides having antiangiogenic activity |
| US20030125259A1 (en) | 2001-10-31 | 2003-07-03 | Fortuna Haviv | Octa- and nonapeptides having antiangiogenic activity |
| US7067490B2 (en) | 2001-10-31 | 2006-06-27 | Abbott Laboratories | Hepta-, Octa-and nonapeptides having antiangiogenic activity |
| US7037897B2 (en) | 2001-10-31 | 2006-05-02 | Abbott Laboratories | TRI-, TETRA-, and penta-peptides having antiangiogenic activity |
| US20030228365A1 (en) * | 2002-06-07 | 2003-12-11 | Fortuna Haviv | Pharmaceutical formulation |
| CA2598833A1 (en) | 2005-03-03 | 2006-09-08 | Curt W. Bradshaw | Anti-angiogenic compounds |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0890101A4 (en) * | 1996-03-05 | 1999-12-08 | Torrey Pines Inst | Selectively n-alkylated peptidomimetic combinatorial libraries and compounds therein |
| IL126626A0 (en) * | 1996-05-03 | 1999-08-17 | Abbott Lab | Novel antiangiogenic peptides polynucleotides encoding same and methods for inhibiting angiogenesis |
| DK0918795T3 (en) * | 1997-03-17 | 2005-03-14 | Abbott Lab | Antiangiogenic drugs for the treatment of cancer, arthritis and retinopathy |
-
2000
- 2000-11-20 CO CO00088047A patent/CO5261544A1/en not_active Application Discontinuation
- 2000-11-22 CA CA002386893A patent/CA2386893A1/en not_active Abandoned
- 2000-11-22 BR BR0010934-7A patent/BR0010934A/en not_active IP Right Cessation
- 2000-11-22 MX MXPA02005139A patent/MXPA02005139A/en not_active Application Discontinuation
- 2000-11-22 JP JP2001540160A patent/JP2003514920A/en not_active Withdrawn
- 2000-11-22 AR ARP000106173A patent/AR026901A1/en unknown
- 2000-11-22 WO PCT/US2000/032105 patent/WO2001038397A1/en active Application Filing
- 2000-11-22 AU AU17913/01A patent/AU1791301A/en not_active Abandoned
- 2000-11-22 EP EP00980685A patent/EP1242455A1/en active Pending
-
2003
- 2003-02-17 HK HK03101124.4A patent/HK1050902A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR0010934A (en) | 2002-12-17 |
| AU1791301A (en) | 2001-06-04 |
| HK1050902A1 (en) | 2003-07-11 |
| CA2386893A1 (en) | 2001-05-31 |
| EP1242455A1 (en) | 2002-09-25 |
| JP2003514920A (en) | 2003-04-22 |
| WO2001038397A1 (en) | 2001-05-31 |
| AR026901A1 (en) | 2003-03-05 |
| MXPA02005139A (en) | 2004-08-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO5261544A1 (en) | N-RENTED PEPTIDES THAT HAVE ANTIANGIOGEN ACTIVITY | |
| DE60233137D1 (en) | TRANSPORTER WITH FILLED ARGININE PARTICLES | |
| ES2126658T3 (en) | COMPOSED OF 2-AMINO-1,3-PROPANODIOL AND IMMUNOSUPPRESSOR. | |
| AU2003301959A1 (en) | Substituted cycloalkyl p1' hepatitis c virus inhibitors | |
| KR900014424A (en) | Amino acid derivatives | |
| AR070809A1 (en) | PEPTIDIC ANTAGONIST CONJUGATES ANALOGS TO THE BOMB | |
| CA2335978A1 (en) | Compounds of unstable dipeptidyl peptidase iv inhibitors | |
| AR061008A1 (en) | INDOLOBENZAZEPINE HCV INHIBITORS FUSIONATED TO CYCLOPROPYL | |
| RU95112539A (en) | New polypeptide and pharmaceutical composition for hiv-infection control | |
| PE20000949A1 (en) | TRIPEPTIDES INHIBITORS OF HEPATITIS C | |
| CO5640126A2 (en) | AMINOALCOHOL DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | |
| ATE192455T1 (en) | COMPOUNDS ACTIVATED BY GLUTATHIONE-S-TRANSFERASE | |
| IL112641A (en) | Broad spectrum antimicrobial compounds and pharmaceutical compositions containing them | |
| MX2022000251A (en) | Compounds comprising a fibroblast activation protein ligand and use thereof. | |
| AR003136A1 (en) | DOLASTATIN PEPTIDES, PROCEDURE FOR PREPARING THEM, THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THE USE OF THEM TO PREPARE SUCH PHARMACEUTICAL COMPOSITIONS. | |
| ATE203412T1 (en) | COMPOSITIONS FOR NASAL ADMINISTRATION OF DESMOPRESSIN | |
| CN101970459A (en) | Antimicrobial compounds | |
| MX2023007869A (en) | Compounds comprising a fibroblast activation protein ligand and use thereof. | |
| AR036192A1 (en) | ANTIBIOTIC PEPTIDES WITH LARGE SPECTRUM ANTIMICROBIAL ACTIVITY AND COMPOSITIONS CONTAINING THEM | |
| KR890006572A (en) | Amino acid derivatives | |
| AR034890A1 (en) | PEPTIDES WITH ANTI-ANGIOGENIC ACTIVITY | |
| AR037165A1 (en) | HEPTA-, OCTA-Y NONAPEPTIDOS WITH ANTIANGIOGEN ACTIVITY. | |
| ATE273318T1 (en) | GST-SPECIFIC MOLECULE RELEASE SYSTEMS BONDED THROUGH URETHANE GROUPS | |
| NZ304437A (en) | Octa- or nona-peptides and therapeutic agent for autoimmune diseases containing the same | |
| AR037166A1 (en) | TETRA-PENTA-, HEXA-Y HEPTAPEPTIDOS WITH ANTIANGIOGEN ACTIVITY. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Application refused |